{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"51.8","value":"35.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Time from date of first dose of study treatment to the date of death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG000","title":"All RP2D (840 mg)"}],"paramType":"MEDIAN","populationDescription":"Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All RP2D population (per protocol).","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}